# SYNAPTICS Inc: financial statements, quarterly SYNA · Nasdaq · CIK 817720 · [Technology](/sectors/technology.md) · fiscal year ends Jun 26 Pages: [Overview](/companies/syna.md) · [Financials](/companies/syna/financials.md) · [Filings](/companies/syna/filings.md) · [Insiders](/companies/syna/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/syna/financials.md?period=annual). ## Income statement | Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-30) | Q3 FY2024 (2024-03-30) | Q4 FY2024 (2024-06-29) | Q1 FY2025 (2024-09-28) | Q2 FY2025 (2024-12-28) | Q3 FY2025 (2025-03-29) | Q4 FY2025 (2025-06-28) | Q1 FY2026 (2025-09-27) | Q2 FY2026 (2025-12-27) | Q3 FY2026 (2026-03-28) | Q4 FY2026 (2026-06-27) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [238](/filings/0001628280-24-046335.md) | [237](/filings/0000817720-25-000011.md) | [237](/filings/0000817720-25-000041.md) | [247 d](/filings/0000817720-26-000055.md) | [258](/filings/0000817720-25-000115.md) | [267](/filings/0000817720-26-000017.md) | [267](/filings/0000817720-26-000036.md) | [283 d](/filings/0000817720-26-000055.md) | [293](/filings/0000817720-25-000115.md) | [303](/filings/0000817720-26-000017.md) | [294](/filings/0000817720-26-000036.md) | [308 d](/filings/0000817720-26-000055.md) | | Cost of revenue | $m | [131](/filings/0001628280-24-046335.md) | [128](/filings/0000817720-25-000011.md) | [127](/filings/0000817720-25-000041.md) | [134 d](/filings/0000817720-26-000055.md) | [137](/filings/0000817720-25-000115.md) | [145](/filings/0000817720-26-000017.md) | [151](/filings/0000817720-26-000036.md) | [161 d](/filings/0000817720-26-000055.md) | [168](/filings/0000817720-25-000115.md) | [171](/filings/0000817720-26-000017.md) | [161](/filings/0000817720-26-000036.md) | [162 d](/filings/0000817720-26-000055.md) | | Gross profit | $m | [107](/filings/0001628280-24-046335.md) | [109](/filings/0000817720-25-000011.md) | [110](/filings/0000817720-25-000041.md) | [113 d](/filings/0000817720-26-000055.md) | [121](/filings/0000817720-25-000115.md) | [122](/filings/0000817720-26-000017.md) | [116](/filings/0000817720-26-000036.md) | [122 d](/filings/0000817720-26-000055.md) | [125](/filings/0000817720-25-000115.md) | [132](/filings/0000817720-26-000017.md) | [133](/filings/0000817720-26-000036.md) | [146 d](/filings/0000817720-26-000055.md) | | Research and development | $m | [86.5](/filings/0001628280-24-046335.md) | [82.0](/filings/0000817720-25-000011.md) | [83.4](/filings/0000817720-25-000041.md) | [84.4 d](/filings/0000817720-26-000055.md) | [81.3](/filings/0000817720-25-000115.md) | [83.3](/filings/0000817720-26-000017.md) | [88.6](/filings/0000817720-26-000036.md) | [93.6 d](/filings/0000817720-26-000055.md) | [94.4](/filings/0000817720-25-000115.md) | [95.1](/filings/0000817720-26-000017.md) | [94.5](/filings/0000817720-26-000036.md) | [97.8 d](/filings/0000817720-26-000055.md) | | Selling, general and administrative | $m | [42.3](/filings/0001628280-24-046335.md) | [39.7](/filings/0000817720-25-000011.md) | [40.5](/filings/0000817720-25-000041.md) | [38.8 d](/filings/0000817720-26-000055.md) | [50.0](/filings/0000817720-25-000115.md) | [49.5](/filings/0000817720-26-000017.md) | [34.7](/filings/0000817720-26-000036.md) | [46.1 d](/filings/0000817720-26-000055.md) | [46.2](/filings/0000817720-25-000115.md) | [47.8](/filings/0000817720-26-000017.md) | [49.6](/filings/0000817720-26-000036.md) | [54.7 d](/filings/0000817720-26-000055.md) | | Operating income | $m | [(35.2)](/filings/0001628280-24-046335.md) | [(17.9)](/filings/0000817720-25-000011.md) | [(17.4)](/filings/0000817720-25-000041.md) | [(31.1) d](/filings/0000817720-26-000055.md) | [(28.4)](/filings/0000817720-25-000115.md) | [(15.2)](/filings/0000817720-26-000017.md) | [(26.3)](/filings/0000817720-26-000036.md) | [(24.2) d](/filings/0000817720-26-000055.md) | [(23.2)](/filings/0000817720-25-000115.md) | [(15.1)](/filings/0000817720-26-000017.md) | [(12.7)](/filings/0000817720-26-000036.md) | [(16.1) d](/filings/0000817720-26-000055.md) | | Interest expense | $m | [11.8](/filings/0001628280-24-046335.md) | [12.0](/filings/0000950170-24-012868.md) | [11.9](/filings/0000950170-24-057227.md) | [29.4 d](/filings/0000950170-24-100261.md) | [11.7](/filings/0001628280-24-046335.md) | [4.3](/filings/0000817720-25-000011.md) | [1.1](/filings/0000817720-25-000041.md) | [28.5 d](/filings/0000817720-26-000055.md) | not reported | not reported | not reported | not reported | | Income tax | $m | [15.0](/filings/0001628280-24-046335.md) | [(15.0)](/filings/0000817720-25-000011.md) | [(5.2)](/filings/0000817720-25-000041.md) | [(245) d](/filings/0000817720-26-000055.md) | [(11.2)](/filings/0000817720-25-000115.md) | [(27.8)](/filings/0000817720-26-000017.md) | [(5.6)](/filings/0000817720-26-000036.md) | [(21.1) d](/filings/0000817720-26-000055.md) | [(2.1)](/filings/0000817720-25-000115.md) | [(2.7)](/filings/0000817720-26-000017.md) | [(7.2)](/filings/0000817720-26-000036.md) | [423 d](/filings/0000817720-26-000055.md) | | Net income | $m | [(55.6)](/filings/0000817720-25-000041.md) | [(9.0)](/filings/0000817720-25-000041.md) | [(18.1)](/filings/0000817720-25-000041.md) | [208 d](/filings/0000817720-26-000055.md) | [(23.1)](/filings/0000817720-26-000036.md) | [1.8](/filings/0000817720-26-000036.md) | [(21.8)](/filings/0000817720-26-000036.md) | [(4.7) d](/filings/0000817720-26-000055.md) | [(20.6)](/filings/0000817720-26-000036.md) | [(14.8)](/filings/0000817720-26-000036.md) | [(8.0)](/filings/0000817720-26-000036.md) | [(447) d](/filings/0000817720-26-000055.md) | | Diluted EPS | $ per share | [(1.43)](/filings/0001628280-24-046335.md) | [(0.23)](/filings/0000817720-25-000011.md) | [(0.46)](/filings/0000817720-25-000041.md) | not reported | [(0.58)](/filings/0000817720-25-000115.md) | [0.05](/filings/0000817720-26-000017.md) | [(0.56)](/filings/0000817720-26-000036.md) | not reported | [(0.53)](/filings/0000817720-25-000115.md) | [(0.38)](/filings/0000817720-26-000017.md) | [(0.21)](/filings/0000817720-26-000036.md) | not reported | | Basic EPS | $ per share | [(1.43)](/filings/0001628280-24-046335.md) | [(0.23)](/filings/0000817720-25-000011.md) | [(0.46)](/filings/0000817720-25-000041.md) | not reported | [(0.58)](/filings/0000817720-25-000115.md) | [0.05](/filings/0000817720-26-000017.md) | [(0.56)](/filings/0000817720-26-000036.md) | not reported | [(0.53)](/filings/0000817720-25-000115.md) | [(0.38)](/filings/0000817720-26-000017.md) | [(0.21)](/filings/0000817720-26-000036.md) | not reported | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-30) | Q3 FY2024 (2024-03-30) | FY2024 (2024-06-29) | Q1 FY2025 (2024-09-28) | Q2 FY2025 (2024-12-28) | Q3 FY2025 (2025-03-29) | FY2025 (2025-06-28) | Q1 FY2026 (2025-09-27) | Q2 FY2026 (2025-12-27) | Q3 FY2026 (2026-03-28) | FY2026 (2026-06-27) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [801](/filings/0000950170-23-062199.md) | [846](/filings/0000950170-24-012868.md) | [828](/filings/0000950170-24-057227.md) | [877](/filings/0000817720-25-000073.md) | [854](/filings/0001628280-24-046335.md) | [596](/filings/0000817720-25-000011.md) | [360](/filings/0000817720-25-000041.md) | [392](/filings/0000817720-26-000055.md) | [460](/filings/0000817720-25-000115.md) | [437](/filings/0000817720-26-000017.md) | [404](/filings/0000817720-26-000036.md) | [443](/filings/0000817720-26-000055.md) | | Current assets | $m | [1,109](/filings/0000950170-23-062199.md) | [1,147](/filings/0000950170-24-012868.md) | [1,123](/filings/0000950170-24-057227.md) | [1,162](/filings/0000817720-25-000073.md) | [1,140](/filings/0001628280-24-046335.md) | [891](/filings/0000817720-25-000011.md) | [713](/filings/0000817720-25-000041.md) | [752](/filings/0000817720-26-000055.md) | [749](/filings/0000817720-25-000115.md) | [771](/filings/0000817720-26-000017.md) | [755](/filings/0000817720-26-000036.md) | [787](/filings/0000817720-26-000055.md) | | Total assets | $m | [2,549](/filings/0000950170-23-062199.md) | [2,573](/filings/0000950170-24-012868.md) | [2,540](/filings/0000950170-24-057227.md) | [2,825](/filings/0000817720-25-000073.md) | [2,791](/filings/0001628280-24-046335.md) | [2,528](/filings/0000817720-25-000011.md) | [2,554](/filings/0000817720-25-000041.md) | [2,584](/filings/0000817720-26-000055.md) | [2,577](/filings/0000817720-25-000115.md) | [2,563](/filings/0000817720-26-000017.md) | [2,522](/filings/0000817720-26-000036.md) | [2,102](/filings/0000817720-26-000055.md) | | Current liabilities | $m | [246](/filings/0000950170-23-062199.md) | [253](/filings/0000950170-24-012868.md) | [211](/filings/0000950170-24-057227.md) | [277](/filings/0000817720-25-000073.md) | [254](/filings/0001628280-24-046335.md) | [230](/filings/0000817720-25-000011.md) | [248](/filings/0000817720-25-000041.md) | [271](/filings/0000817720-26-000055.md) | [262](/filings/0000817720-25-000115.md) | [263](/filings/0000817720-26-000017.md) | [248](/filings/0000817720-26-000036.md) | [701](/filings/0000817720-26-000055.md) | | Total liabilities | $m | [1,344](/filings/0000950170-23-062199.md) | [1,353](/filings/0000950170-24-012868.md) | [1,304](/filings/0000950170-24-057227.md) | [1,358](/filings/0000817720-25-000073.md) | [1,324](/filings/0001628280-24-046335.md) | [1,151](/filings/0000817720-25-000011.md) | [1,167](/filings/0000817720-25-000041.md) | [1,190](/filings/0000817720-26-000055.md) | [1,177](/filings/0000817720-25-000115.md) | [1,180](/filings/0000817720-26-000017.md) | [1,164](/filings/0000817720-26-000036.md) | [1,173](/filings/0000817720-26-000055.md) | | Long-term debt | $m | [970](/filings/0000950170-23-062199.md) | [969](/filings/0000950170-24-012868.md) | [968](/filings/0000950170-24-057227.md) | [967](/filings/0000817720-25-000073.md) | [966](/filings/0001628280-24-046335.md) | [833](/filings/0000817720-25-000011.md) | [834](/filings/0000817720-25-000041.md) | [835](/filings/0000817720-26-000055.md) | [835](/filings/0000817720-25-000115.md) | [836](/filings/0000817720-26-000017.md) | [837](/filings/0000817720-26-000036.md) | [398](/filings/0000817720-26-000055.md) | | Current portion of debt | $m | not reported | not reported | not reported | [6.0](/filings/0000817720-25-000073.md) | not reported | not reported | not reported | [0.0](/filings/0000817720-26-000055.md) | not reported | not reported | not reported | [440](/filings/0000817720-26-000055.md) | | Shareholders' equity | $m | [1,204](/filings/0000817720-25-000041.md) | [1,220](/filings/0000817720-25-000041.md) | [1,235](/filings/0000817720-25-000041.md) | [1,467](/filings/0000817720-26-000055.md) | [1,467](/filings/0000817720-26-000036.md) | [1,376](/filings/0000817720-26-000036.md) | [1,387](/filings/0000817720-26-000036.md) | [1,395](/filings/0000817720-26-000055.md) | [1,401](/filings/0000817720-26-000036.md) | [1,384](/filings/0000817720-26-000036.md) | [1,359](/filings/0000817720-26-000036.md) | [930](/filings/0000817720-26-000055.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: us-gaap:LongTermDebtCurrent - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-30) | Q3 FY2024 (2024-03-30) | Q4 FY2024 (2024-06-29) | Q1 FY2025 (2024-09-28) | Q2 FY2025 (2024-12-28) | Q3 FY2025 (2025-03-29) | Q4 FY2025 (2025-06-28) | Q1 FY2026 (2025-09-27) | Q2 FY2026 (2025-12-27) | Q3 FY2026 (2026-03-28) | Q4 FY2026 (2026-06-27) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [45.4](/filings/0001628280-24-046335.md) | [39.2 d](/filings/0000817720-25-000011.md) | [(13.7) d](/filings/0000817720-25-000041.md) | [65.0 d](/filings/0000817720-26-000055.md) | [(11.4)](/filings/0000817720-25-000115.md) | [22.8 d](/filings/0000817720-26-000017.md) | [73.4 d](/filings/0000817720-26-000036.md) | [57.2 d](/filings/0000817720-26-000055.md) | [30.2](/filings/0000817720-25-000115.md) | [29.8 d](/filings/0000817720-26-000017.md) | [21.8 d](/filings/0000817720-26-000036.md) | [67.6 d](/filings/0000817720-26-000055.md) | | Capital expenditure | $m | [6.7](/filings/0001628280-24-046335.md) | [10.4 d](/filings/0000817720-25-000011.md) | [9.0 d](/filings/0000817720-25-000041.md) | [7.7 d](/filings/0000817720-26-000055.md) | [9.1](/filings/0000817720-25-000115.md) | [4.7 d](/filings/0000817720-26-000017.md) | [5.4 d](/filings/0000817720-26-000036.md) | [6.6 d](/filings/0000817720-26-000055.md) | [12.2](/filings/0000817720-25-000115.md) | [11.6 d](/filings/0000817720-26-000017.md) | [11.9 d](/filings/0000817720-26-000036.md) | [12.3 d](/filings/0000817720-26-000055.md) | | Share repurchases | $m | [0.0](/filings/0000950170-23-062199.md) | [0.0 d](/filings/0000817720-25-000011.md) | [0.0 d](/filings/0000817720-25-000041.md) | [0.0 d](/filings/0000817720-26-000055.md) | [0.0](/filings/0000817720-25-000115.md) | [74.5 d](/filings/0000817720-26-000017.md) | [37.8 d](/filings/0000817720-26-000036.md) | [16.0 d](/filings/0000817720-26-000055.md) | [7.2](/filings/0000817720-25-000115.md) | [36.4 d](/filings/0000817720-26-000017.md) | [39.0 d](/filings/0000817720-26-000036.md) | [10.1 d](/filings/0000817720-26-000055.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q1 FY2023 (2022-09-24) | Q2 FY2023 (2022-12-24) | Q3 FY2023 (2023-03-25) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-30) | Q3 FY2024 (2024-03-30) | Q1 FY2025 (2024-09-28) | Q2 FY2025 (2024-12-28) | Q3 FY2025 (2025-03-29) | Q1 FY2026 (2025-09-27) | Q2 FY2026 (2025-12-27) | Q3 FY2026 (2026-03-28) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [0.0](/filings/0000950170-23-062199.md) | [0.0](/filings/0000950170-24-012868.md) | [0.0](/filings/0000950170-24-057227.md) | [38.8](/filings/0001628280-24-046335.md) | [39.2](/filings/0000817720-25-000011.md) | [39.3](/filings/0000817720-25-000041.md) | [39.8](/filings/0000817720-25-000115.md) | [39.8](/filings/0000817720-26-000017.md) | [39.0](/filings/0000817720-26-000036.md) | [38.8](/filings/0000817720-25-000115.md) | [38.9](/filings/0000817720-26-000017.md) | [38.8](/filings/0000817720-26-000036.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 39,106,986 at 2026-08-04, from the cover of the [10-K filed 2026-08-10](/filings/0000817720-26-000055.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:25 ET. No prices; not investment advice.